Anti-AML effect of AT1413 in vivo. (A) HIS mice with human AML (luciferase-GFP transduced SH2) received biweekly treatment with AT1413 or control antibody AT1002 (15 mg/kg IV, indicated by asterisk). AML progression was measured by bioluminescence (CPM) after luciferase injection. (B) Bioluminescence of individual organs harvested after mice were sacrificed. (C) Human T cells, B cells, NK cells, and granulocytes, expressed as proportion of human CD45⁺ hematopoietic cells (excluding CD45dim AML cells) in blood and bone marrow of AT1413- and AT1002-treated mice.